Urigen Announces Recent Insider Purchases Total Over 500,000 Shares

• Press Release
• Source: Urigen Pharmaceuticals
• On 8:29 am EST, Wednesday February 4, 2009

SAN FRANCISCO, CA--(MARKET WIRE)--Feb 4, 2009 -- Urigen Pharmaceuticals, Inc. (OTC BB:URGP.OB - News), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announces that insiders have recently purchased over 500,000 shares. These purchases are detailed on Form 4s filed with the Securities and Exchange Commission. William J. Garner, MD, President and CEO of Urigen, states, "These recent purchases made by a handful of Board members should indicate our confidence in our technologies, particularly with respect to the recently issued patent covering URG101, the positive double-blind, placebo-controlled phase II URG101 data, and in our ability to execute on our recently announced partnering activities."

Related Quotes

Symbol	Price	Change
URGP.OB	0.07	-0.01

{"s" : "urgp.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101, a proprietary combination of approved drugs that is instilled into the bladder, targets painful bladder syndrome, which affects approximately 10.5 million men and women in North America. Urigen's URG301, a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency, targets acute urgency in females diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. For further information, please visit Urigen's website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Urigen has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Urigen believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Urigen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

     Contact:
      
     Urigen Pharmaceuticals, Inc.
     William J. Garner, MD
     Chief Executive Officer
     415-781-0350
     http://www.urigen.com